Open Access
Numéro
Ann Toxicol Anal
Volume 21, Numéro 1, 2009
Page(s) 13 - 19
DOI https://doi.org/10.1051/ata/2009033
Publié en ligne 12 mai 2009
  1. Obradovik I, Canarelli T. An analysis of medical practices in hospital and penal environments since the introduction of the circular dated january 30, 2002. Tendances No. 60, avril 2008. http://www.ofdt.fr/BDD/publications/docs/eftxioo4.pdf
  2. Circulaire DGS No. 14 du 7 mars 1994 relative au cadre d'utilisation de la méthadone dans la prise en charge des toxicomanes.
  3. Circulaire DGS/DHOS No. 2002/57 du 30 janvier 2002 relative à la prescription de la méthadone par les médecins exerçant en établissement de santé, dans le cadre de l'initialisation d'un traitement de substitution pour les toxicomanes dépendants majeurs aux opiacés. http://mildt.systalium.org/article672.html
  4. Varescon I, Vidal-Trécan G, Nabet N, Boissonas A. Substitution et mésusage : l'injection intraveineuse de buprénorphine haut dosage. L'Encéphale. 2002; 28: 397-402.
  5. Duverneuil C, Etting I, Paraire F, Lorin de la Grandmaison G, Durigon M, de Mazancourt P, Alvarez JC. Intérêt des analyses toxicologiques lors d'une recherche des causes de décès (résultats de 358 analyses). Ann Toxicol Anal. 2005; 17(3): 187-193. [CrossRef] [EDP Sciences]
  6. Kristensen K, Christensen CB, Christrup LL. The Formula 1, Formula 2, Formula , Formula opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995; 56: 45-50. [CrossRef] [PubMed]
  7. Vazquez V, Gury C, Laqueille X. Methadone: from pharmacokinetic profile to clinical pharmacology. Encephale. 2006; 32: 478-486. [CrossRef] [PubMed]
  8. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, Kreek MJ. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet. 2008; 17(14): 2219-2227. [CrossRef] [PubMed]
  9. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000; 50(5): 427-440. [CrossRef] [PubMed]
  10. Boglione-Kerrien C, Furet Y, Bachellier J, Paintaud G, Autret-Leca E. Methadone blood assay by the FPIA technique: application to the monitoring of patients in maintenance treatment to opiates. Ann Biol Clin. 2007; 65(1): 51-57.
  11. Cone EJ, Caplan YH, Black DL, Robert T, Moser F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008; 32(8): 530-543. [CrossRef] [PubMed]
  12. Bézie Y, Talon V, Lillo A, Illier C, Billaud E, Prognon P, Boutouyrie P. Compliance with methadone-based substitutive treatment: a proposed model based on immunoassay urinary sample screening. Ther Drug Monit. 2004; 26(3): 271-276. [CrossRef] [PubMed]
  13. George S, Parmar S, Meadway C, Braithwaite RA. Application and validation of a urinary methadone metabolite (EDDP) immunoassay to monitor methadone compliance. Ann Clin Biochem. 2000; 37(3): 350-354. [CrossRef] [PubMed]
  14. Preston KL, Epstein DH, Davoudzadeh D, Huestis MA. Methadone and metabolite urine concentrations in patients maintained on methadone. J Anal Toxicol. 2003; 27(6): 332-341. [CrossRef] [PubMed]
  15. Kell MJ, Techman T. Rapid measurement of plasma methadone in a clinical setting using florescence polarization immunoassay. J Addict Dis. 1996; 15(2): 69-83. [CrossRef] [PubMed]
  16. Juhascik M, Habbel S, Barron W, Behonick G. Validation of an ELISA method for screening methadone in postmortem blood. J Anal Toxicol. 2006; 30(8): 617-620. [CrossRef] [PubMed]
  17. Chikhi-Chorfi N, Galons H, Pham-Huy C, Thevenin M, Warnet JM, Claude JR. Selective antibodies to methadone enantiomers: synthesis of (R)- and (R,S)-methadone conjugates and determination by an immunoenzymatic method in human serum. Chirality. 2001; 13(4): 187-192. [CrossRef] [PubMed]
  18. Cone EJ, Clarke J, Tsanaclis L. Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid. J Anal Toxicol. 2007; 31(8): 424-433. [CrossRef] [PubMed]
  19. Moore L, Wicks J, Spiehler V, Holgate R. Gas chromatography-mass spectrometry confirmation of Cozart RapiScan saliva methadone and opiates tests. J Anal Toxicol. 2001; 25(7): 520-524. [CrossRef] [PubMed]
  20. Cooper G, Wilson L, Reid C, Baldwin D, Hand C, Spiehler V. Comparison of GC-MS and EIA results for the analysis of methadone in oral fluid. J Forensic Sci. 2005; 50(4): 928-932. [CrossRef] [PubMed]
  21. Cooper G, Wilson L, Reid C, Baldwin D, Hand C, Spiehler V. Comparison of Cozart microplate ELISA and GC-MS detection of methadone and metabolites in human hair. J Anal Toxicol. 2005; 29: 678-681. [CrossRef] [PubMed]
  22. elSohly MA, Feng S, Murphy TP. Analysis of methadone and its metabolites in meconium by enzyme immunoassay (EMIT) and GC-MS. J Anal Toxicol. 2001; 25(1): 40-44. [CrossRef] [PubMed]
  23. Widschwendter CG, Zernig G, Hofer A. Quetiapine cross reactivity with urine methadone immunoassays. Am J Psychiatry. 2007; 164(1): 172. [CrossRef]
  24. Lichtenwalner MR, Mencken T, Tully R, Petosa M. False-positive immunochemical screen for methadone attributable to metabolites of verapamil. Clin Chem. 1998; 44(5): 1039-1041. [PubMed]
  25. Lancelin F, Kraoul L, Flatischler N, Brovedani-Rousset S, Piketty ML. False-positive results in the detection of methadone in urines of patients treated with psychotropic substances. Clin Chem. 2005; 51(11): 2176-2177. [CrossRef] [PubMed]
  26. Kelner MJ. Positive diphenhydramine interference in the EMIT-d.a.u. assay. Clin Chem. 1984; 30(8): 1430. [PubMed]
  27. Hausmann E, Kohl B, von Boehmer H, Wellhöner HH. False-positive EMIT indication of opiates and methadone in a doxylamine intoxication. J Clin Chem Clin Biochem. 1983; 21(10): 599-600. [PubMed]
  28. Al-Asmari AI, Anderson RA. Comparison of nonhydrolysis and hydrolysis methods for the determination of buprenorphine metabolites in urine by liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2008; 39(9): 744-753. [CrossRef]
  29. Cirimele V, Etienne S, Villain M, Ludes B, Kintz P. Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens. Forensic Sci Int. 2004; 143(2-3): 153-156. [CrossRef] [PubMed]
  30. Cirimele V, Kintz P, Lohner S, Ludes B. Enzyme immunoassay validation for the detection of buprenorphine in urine. J Anal Toxicol. 2003; 27(2): 103-105. [CrossRef] [PubMed]
  31. Miller EI, Torrance HJ, Oliver JS. Validation of the Immunalysis microplate ELISA for the detection of buprenorphine and its metabolite norbuprenorphine in urine. J Anal Toxicol. 2006; 30(2): 115-119. [CrossRef] [PubMed]
  32. Wang G, Vincent M, Rodrigues W, Agrawal A, Moore C, Barhate R, Abolencia E, Coulter C, Soares J, Zheng YF, Taylor C, Morjana N. Development and GC-MS validation of a highly sensitive recombinant G6PDH-based homogeneous immunoassay for the detection of buprenorphine and norbuprenorphine in urine. J Anal Toxicol. 2007; 31(7): 377-382. [CrossRef] [PubMed]
  33. Hull MJ, Bierer MF, Griggs DA, Long WH, Nixon AL, Flood JG. Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. J Anal Toxicol. 2008; 32(7): 516-521. [CrossRef] [PubMed]
  34. Böttcher M, Beck O. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J Anal Toxicol. 2005; 29(8): 769-776. [CrossRef] [PubMed]
  35. Wilkins DG, Rollins DE, Valdez AS, Mizuno A, Krueger GG, Cone EJ. A retrospective study of buprenorphine and norbuprenorphine in human hair after multiple doses. J Anal Toxicol. 1999; 23(6): 409-415. [CrossRef] [PubMed]
  36. Goodwin RS, Wilkins DG, Averin O, Choo RE, Schroeder JR, Jasinski DR, Johnson RE, Jones HE, Huestis MA. Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration. Clin Chem. 2007; 53(12): 2136-2143. [CrossRef] [PubMed]
  37. McNally AJ, Pilcher I, Wu R, Salamone SJ, Brewington S, King JW, Irving J. Evaluation of the online immunoassay for propoxyphene: comparison to EMIT II and GC-MS. J Anal Toxicol. 1996; 20(7): 537-540. [CrossRef] [PubMed]
  38. Kintz P, Mangin P. Abbott propoxyphene assay: evaluation and comparison of TDx FPIA and GC/MS methods. J Anal Toxicol. 1993; 17(4): 222-224. [CrossRef] [PubMed]
  39. Poklis A, Poklis JL, Tarnai LD, Backer RC. Evaluation of the Triage PPY on-site testing device for the detection of dextropropoxyphene in urine. J Anal Toxicol. 2004; 28(6): 485-8. [CrossRef] [PubMed]
  40. Moore C, Marinetti L, Coulter C, Crompton K. Analysis of pain management drugs, specifically fentanyl, in hair: application to forensic specimens. Forensic Sci Int. 2008; 176(1): 47-50. [CrossRef] [PubMed]
  41. Ruangyuttikarn W, Law MY, Rollins DE, Moody DE. Detection of fentanyl and its analogs by enzyme-linked immunosorbent assay. J Anal Toxicol. 1990; 14(3): 160-164. [CrossRef] [PubMed]
  42. Smith ML, Hughes RO, Levine B, Dickerson S, Darwin WD, Cone EJ. Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol. 1995; 19(1): 18-26. [CrossRef] [PubMed]
  43. Backer RC, Monforte JR, Poklis A. Evaluation of the DRI oxycodone immunoassay for the detection of oxycodone in urine. J Anal Toxicol. 2005; 29(7): 675-677. [CrossRef] [PubMed]
  44. Haller CA, Stone J, Burke V, Branch J, Chen K, Gross S. Comparison of an automated and point-of-care immunoassay to GC-MS for urine oxycodone testing in the clinical laboratory. J Anal Toxicol. 2006; 30(2): 106-111. [CrossRef] [PubMed]